Jiangsu Hengrui Pharmaceuticals (01276): HRS-8364 tablets receive clinical trial approval notification letter.

Jiangsu Hengrui Pharmaceuticals (01276) announced that the company recently received the approval notice from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, and will soon commence the clinical trial. HRS-8364 is an innovative anti-tumor drug independently developed by the company, intended for the treatment of late-stage solid tumors. Upon inquiry, there is currently no similar approved drug on the market both domestically and internationally. As of now, the total research and development expenditure for the HRS-8364 tablet project is approximately 21.65 million yuan.